BB, VPLM SAYS .0245 BRO FROM .015 CALL:)) ORCA Member Level Re: i_like_bb_stock post# 4913418 Thursday, December 22, 2022 2:28:27 PM Post# 4913437 of 4915869 VPLM.015.A MUST READ PR FROM YEARS AGO.THINGS ARE FAVORING VPLM.JANUARY THE COURTS STARTING.AND BY END OF MAY 2023 LOOKS LIKE FINALLY AWARDS WILL BE GIVEN.SETTLEMENTS. LOOKING AT THE NUMBERS BELOW IN THE OLD PR,WE ARE LOOKING AT $$$ STOCK.KEEP IT ON THE MONITOR BB.LOOKS LIKE FINALLY 2023 VPLM WILL MAKE SOME HUGE BANK FINALLY.IMO. https://www.globenewswire.com/fr/news-release/2017/05/15/984693/0/en/Voip-Pal-Com-Announces-Plans-to-Increase-Damage-Demands-in-Lawsuits-vs-Apple-Verizon-and-AT-T.html Voip-Pal.Com Announces Plans to Increase Damage Demands in Lawsuits vs Apple, Verizon and AT&T Company preparing responses to new petitions for Inter Partes Review 15 mai 2017 05h00 HE | Source: Voip-Pal.Com Inc. BELLEVUE, Wash., May 15, 2017 (GLOBE NEWSWIRE) -- Voip-Pal.com, Inc. (“Voip-Pal,” the “Company”) (OTCQB:VPLM) announces their intent to increase the damage claims in its lawsuits against Apple, Verizon and AT&T. Over the past few months the Company has been reevaluating the initial damage calculation claims made in its February 2016, lawsuits against Apple, Inc, in the United States District Court, District of Nevada case number 2:16-CV-00260, Cellco Partnership d/b/a Verizon Wireless and AT&T Corp. in the United States District Court, District of Nevada, case number 2:16-cv-00271. Voip-Pal has determined its initial claim for damages was calculated using a significantly lower royalty monetization model than has been used in actual court awards of recent patent infringement cases.
Voip-Pal remains cautiously conservative with its newly revised calculations, using an amount 25% below actual recent court awards for damages. Upon the lifting of the current stay pending the completion of the instituted Inter Partes Reviews expected later this year, the Company may file an amended pleading to reflect the more accurate damage calculation model.
Utilizing the updated damages award calculation methods, the revised total damages sought by Voip-Pal from Apple would rise from more than two billion dollars ($2,836,710,031), to more than twenty-five billion dollars ($25,642,557,840).
An award in Voip-Pal’s favor may also include additional punitive damages awarded by the court, up to triple damages increasing the newly revised potential maximum total award to Voip-Pal to over one hundred two billion dollars, ($102,570,231,360).
Applying the updated damage award calculation method to Verizon and AT&T, the current damages sought from Verizon of more than two billion dollars ($2,382,872,100) would increase to over seventeen billion dollars ($17,262,042,011).
The current damages sought from AT&T would increase from more than one billion dollars ($1,804,795,745) to over thirteen billion dollars ($13,540,863,431).
Applying the maximum potential punitive damages, increases the maximum potential award from Verizon to more than sixty-nine billion dollars ($69 billion).
Applying the maximum potential punitive damages, increases the maximum potential award from AT&T to more than fifty-four billion dollars ($54 billion).
The complete monetization analyses and damage calculation methodologies will be posted on www.voip-pal.com.
The Company also reports the filing of five more petitions for Inter Partes Review (IPR) from AT&T and Apple. The deadline for filing an IPR petition by Apple, Verizon and AT&T was May 9, 2017, one year from the date of the completion of service of process to the defendants.
On May 8, 2017, AT&T filed the following three petitions for Inter Partes Review: IPR2017-01382, against Voip-Pal’s Patent No. 8,542,815, IPR2017-01383, against Voip-Pal’s Patent No. 9,179,005, and IPR2017-01384, against Voip-Pal’s Patent No. 9,179,005.
On May 9, 2017, Apple filed the following two petitions for Inter Partes Review: IPR2017-01399, against Voip-Pal’s Patent No. 8,542,815, and IPR2017-01398 against Voip-Pal’s Patent No. 9,179,005.
Voip-Pal CEO Emil Malak stated, “We will continue to vigorously defend these challenges to our technology and protect the interests of our shareholders. Once the stay is lifted we will make a final determination on amending the asserted damages of our lawsuits with Apple, Verizon and AT&T.”
“We are now faced with defending five new IPR’s, three filed by ATT and two filed by Apple, all on the same two patents we have been defending for the past year. We are confident we will prevail based on the merits. We appreciate the patience of our shareholders and we assure them we will persevere to a successful end.”
About Voip-Pal.com Inc. Voip-Pal.Com Inc. is a publicly traded corporation (OTCQB:VPLM) headquartered in Bellevue, Washington. The Company owns a portfolio of patents relating to Voice-over-Internet Protocol (“VoIP”) technology that it is currently looking to monetize.
Corporate Website: www.voip-pal.com IR inquiries: IR@voip-pal.com IR Contact: Rich Inza (954) 495-4600
VDRM, HIGH OF .0095 BB.FROM CALL OF .006 THIS MORNING BRO:) ORCA Member Level Re: i_like_bb_stock post# 4915721 Thursday, January 12, 2023 9:17:29 AM Post# 4915743 of 4915870 VDRM.006.TREMENDOUS NEWS OUT.READ ALL BOLD.ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development ViaDerma also announced they are continuing to pursue several large purchase orders they are confident could be finalized soon. Press Release | 01/12/2023 LOS ANGELES, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (OTC Pink: VDRM) is pleased to announce that they have engaged the growth marketing services of INTENT SCIENCES who will help grow the business online with brand development, go-to-marketing strategies, search engine optimization, social media, content marketing, and more this year.
INTENT SCIENCES has a proven track record of achieving exceptionally high growth results very cost-effectively for a wide range of companies around the world - from startups & small businesses to leading Fortune 500 brands across a variety of industries. Their distributed team of digital marketing experts specializes in scaling out personalized digital marketing growth systems that have helped produce over $1 Billion in sales revenue online for dozens of brands to date. To learn more, see their experience.
“We’re very honored and excited to be working with ViaDerma to help grow the brand and business online. Vitastem Ultra is an incredible first aid & antibiotic treatment that works miracles. The world really needs to know about the immense value Vitastem provides and we will be working very hard to make that happen,” said INTENT SCIENCES Founder & CEO, Michael Balducci.
The INTENT SCIENCES team will be working closely with ViaDerma management to help grow the B2B & DTC demand side for ViaDerma licensing and lead product Vitastem Ultra.
“The consumer demand is off the charts for the many ailments Vitastem is a great solution for. According to primary data from Google, there are over 35 million searches on average each month in the US alone for several infectious skin diseases that Vitastem is an immediate remedy for. From psoriasis, eczema, diabetic ulcers, acne scars, MRSA, and impetigo, to healing cuts & scrapes, surgical wounds, toenail fungus, first to third-degree burns, and pet wounds too. We intend to help connect Vitastem with the massive amount of consumer search demand online via very advanced SEO strategies, amongst other ongoing digital brand awareness campaigns too,” said Balducci.
ViaDerma President & CEO, Dr. Chris Otiko said, “We are thrilled to bring INTENT SCIENCES in at this time to help us move forward in this new year. We have seen their results with other companies, and we are convinced they will be a perfect fit to help us build the Vitastem brand and greatly increase our revenues for 2023 and beyond.”
ViaDerma also announced they are continuing to pursue several large purchase orders they are confident could be finalized soon.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
News 
Market Data 
Discover 
AI
